妊娠期维多珠单抗暴露:炎症性肠病临床研究中的结局
该研究汇总了维多珠单抗临床项目及上市后妊娠数据,评估女性及男性伴侣的妊娠结局。临床项目六项研究共27例女性妊娠和19例男性伴侣妊娠,上市后报告81例妊娠。作者认为样本量和随访有限,未发现新的安全性信号,但维多珠单抗仅在获益大于风险时用于妊娠期。
要点
- 临床项目六项研究共27例女性妊娠和19例男性伴侣妊娠,上市后报告81例妊娠
- 24例接受维多珠单抗的女性中11例活产、5例选择性终止、4例自然流产、4例结局未记录
- 作者认为样本量和随访有限,未发现新的妊娠结局安全性信号
核心结论
- 初步分析受样本量和随访限制,未发现女性直接或间接暴露于维多珠单抗后妊娠结局有新的安全性信号。
- 维多珠单抗仅在母亲获益大于对母亲或未出生孩子的风险时才应在妊娠期使用。
研究设计与样本
- 分析临床项目(2007年5月14日至2013年6月27日)及上市后(至2015年11月19日)收集的所有妊娠数据。
- 临床项目共六项研究,包括女性参与者27例妊娠和男性参与者伴侣19例妊娠。
- 上市后报告记录81例妊娠。
主要发现
- 24例接受维多珠单抗的女性(23例克罗恩病或溃疡性结肠炎,1例健康志愿者)中,11例活产、5例选择性终止、4例自然流产、4例结局未记录。
- 1例健康志愿者在估计受孕前79天暴露于单剂维多珠单抗,其活产婴儿报告先天性胼胝体发育不全异常。
- 男性参与者伴侣19例妊娠中,11例活产、2例自然流产、3例选择性终止、3例结局未记录。
- 上市后报告81例妊娠中,4例活产、11例自然流产、66例妊娠在进行中或报告结局未记录。
临床怎么用
- 作者认为,维多珠单抗仅在母亲获益大于对母亲或未出生孩子的风险时才应在妊娠期使用。
局限性
- 作者指出初始分析受样本量限制。
- 作者指出初始分析受随访限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vedolizumab is a gut-selective immunoglobulin G1 monoclonal antibody to α4 β7 integrin for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Prospective clinical studies of vedolizumab in pregnancy have not been conducted; therefore, existing safety data of vedolizumab in pregnancy were examined. AIM: To assess pregnancy outcomes in females and partners of males who received vedolizumab. METHODS: All pregnancy data collected during the clinical programme (from 14 May 2007 to 27 June 2013) and in the post-marketing setting (to 19 November 2015) were analysed. RESULTS: Across six studies, there were 27 pregnancies in female participants and 19 pregnancies in partners of male participants. Among 24 vedolizumab-treated females (23 with CD/UC, one healthy volunteer), there were 11 live births, five elective terminations, four spontaneous abortions and four undocumented outcomes. A congenital corpus callosum agenesis anomaly was reported in one live birth from a healthy volunteer with extensive obstetric history exposed to single-dose vedolizumab 79 days before estimated conception. Of 19 pregnancies in partners of male participants, there were 11 live births, two spontaneous abortions, three elective terminations and three undocumented outcomes. Post-marketing reports recorded 81 pregnancies, resulting in four live births, 11 spontaneous abortions and 66 pregnancies that were on-going or reported undocumented outcomes. CONCLUSIONS: Initial analysis, limited by sample size and follow-up, identified no new safety concerns for pregnancy outcomes in females directly or indirectly exposed to vedolizumab. However, vedolizumab should be used during pregnancy only if the benefits to the mother outweigh the risks to the mother/unborn child.
引用
- Mahadevan U, Vermeire S, Lasch K, et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther. 2017. PMID: 28169436. doi:10.1111/apt.13960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。